No adjustment within stated limits
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding CrCl 30-90 mL/min does not require a renal dose change. Safety and efficacy below 30 mL/min remain unestablished for this fixed combination. Limits and monitoring Verify all components and concomitant renin-angiotensin system inhibitors. Follow potassium and renal function. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 36, posted Feb 18, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding CrCl 30-90 mL/min does not require a renal dose change. Safety and efficacy below 30 mL/min remain unestablished for this fixed combination. Limits and monitoring Verify all components and concomitant renin-angiotensin system inhibitors. Follow potassium and renal function. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 34, posted Oct 30, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Indexed GFR/eGFR, mL/min/1.73 m2 Renal action or finding In SLE, anifrolumab clearance at eGFR 30-89 mL/min/1.73 m2 resembled that at normal renal function. Limits and monitoring The analysis supplies no severe-impairment or dialysis regimen. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 16, posted Oct 05, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Indexed GFR/eGFR, mL/min/1.73 m2 Renal action or finding In patients with MDRD eGFR 30-89 mL/min/1.73 m2 there was no clinically important difference in exposure to apalutamide or its active metabolite. Limits and monitoring Do not extrapolate the exposure analysis to dialysis. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 29, posted Jul 06, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure Serum creatinine (mg/dL), age (years) and weight (kg) Renal action or finding For adult nonvalvular AF, use 2.5 mg twice daily when at least two are present: age 80 years or older, body weight 60 kg or less, or serum creatinine at least 1.5 mg/dL. Limits and monitoring The AF criteria do not determine the adult VTE regimen. Dialysis patients were excluded from efficacy trials and dialysis recommendations rely on exposure data. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 5, posted Sep 25, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure Cockcroft-Gault CrCl, mL/min Renal action or finding For adults with CrCl below 30 mL/min, use immediate-release apremilast. Give only the morning doses during titration and use 30 mg once daily for maintenance. Limits and monitoring The XR formulation is not recommended in severe renal impairment. Children have separate weight-specific instructions. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 38, posted Sep 11, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Renal impairment is not expected to meaningfully affect exposure after a single 32 mg IV dose of aprepitant for postoperative nausea and vomiting prevention. Limits and monitoring This finding concerns the single-dose IV emulsion regimen. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 8, posted Apr 09, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Oral aprepitant requires no renal dose change, including in ESRD with hemodialysis. Limits and monitoring Confirm the intended capsule regimen and interacting antiemetics or chemotherapy. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 43, posted Nov 06, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding At CrCl below 30 mL/min, monitor arsenic trioxide toxicity frequently. A dose reduction may be needed. Limits and monitoring Follow the product's cardiac, electrolyte and other toxicity-monitoring instructions. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 21, posted Sep 24, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Indexed GFR/eGFR, mL/min/1.73 m2 Renal action or finding Asciminib requires no renal reduction at eGFR 15-89 mL/min/1.73 m2 in patients who do not require dialysis. Limits and monitoring Dialysis lies outside the cited recommendation. Select the underlying regimen by indication. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 13, posted Sep 29, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure GFR/eGFR in mL/min as reported by the source Renal action or finding The patch needs no renal dose change over the studied GFR range of 15-90 mL/min. Limits and monitoring The source does not establish a dialysis dose. Verify that the order is for the asenapine transdermal system. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 13, posted Feb 03, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Usual atazanavir dosing applies to nondialysis renal impairment. In treatment-naive adults with ESRD on HD use atazanavir 300 mg with ritonavir 100 mg once daily; treatment-experienced adults on HD should avoid this regimen. Limits and monitoring Confirm HIV treatment history, boosting and other antiretrovirals before using the recommendation. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 37, posted Jul 18, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Return to top Find another drug
